04:23 AM EDT, 08/13/2024 (MT Newswires) -- Actuate Therapeutics (ACTU) said late Monday it priced its initial public offering of 2.8 million shares at $8 per share for gross proceeds of $22.4 million.

The company granted the underwriters a 30-day option to purchase up to 420,000 additional shares to cover over-allotments.

The shares are due to begin trading on the Nasdaq Global Market on Tuesday under the symbol "ACTU." The offering is expected to close on Wednesday.